The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Politics

Senate confirms Dr Marty Makary as Trump’s FDA chief

by admin March 26, 2025
March 26, 2025
Senate confirms Dr Marty Makary as Trump’s FDA chief

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday.

His confirmation was cemented just hours after he cleared one last procedural test vote earlier in the evening. 

The Senate voted 56-44 to invoke cloture on the nomination prior to his final confirmation.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he will now lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
GOP senator says Dr Oz ignored his questions on transgender issues, abortion
next post
Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

Related Posts

Watchdog group sues Biden admin for docs related...

April 17, 2024

JD Vance vows Trump would not impose federal...

August 26, 2024

‘Colonies problem’: Delegate’s mic cut after outcry during...

January 4, 2025

Mitt Romney names who he thinks will be...

December 16, 2024

Israeli Prime Minister Netanyahu criticizes military’s plans for...

June 17, 2024

Violent attack reignites BOWSER Act debate as Trump...

August 7, 2025

Barrett says justices ‘wear black, not red or...

September 9, 2025

US and Russia draft peace plan for Ukraine...

November 21, 2025

Dems threatening government shutdown over Elon Musk hate,...

March 11, 2025

Hegseth faces latest battle defending his defense secretary...

April 25, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • The Real Drivers of This Market: AI, Semis & Robotics

      February 2, 2026
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      February 2, 2026
    • Tax season scams surge as filing confusion grows

      February 2, 2026
    • Trump considers legal action against Michael Wolff and Epstein estate after latest document release

      February 2, 2026
    • Senate Republicans push for House GOP rebellion against funding package, voter ID legislation

      February 2, 2026
    • Trump announces two-year closure of Trump Kennedy Center for major renovations

      February 2, 2026

    Categories

    • Business (1,449)
    • Politics (5,684)
    • Stocks (1,929)
    • Uncategorized (45)
    • World News (1,442)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved